Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$164.15 +2.3%	$153.78	$111.09 ▼ $169.37	$8.70B	0.54	489,499 shs	560,181 shs
GMAB Genmab A/S	$20.59 +0.2%	$20.47	$17.24 ▼ $30.41	$13.63B	1.07	1.05 million shs	715,774 shs
RDY Dr. Reddy's Laboratories	$13.81 -1.4%	$13.17	$12.26 ▼ $16.89	$11.69B	0.51	1.47 million shs	1.94 million shs
RNA Avidity Biosciences	$30.84 -0.3%	$29.28	$21.51 ▼ $56.00	$3.71B	1.01	1.41 million shs	917,463 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	0.00%	-0.55%	+3.93%	+28.04%	+14.65%
GMAB Genmab A/S	0.00%	+2.74%	+2.23%	-2.56%	-27.68%
RDY Dr. Reddy's Laboratories	0.00%	+0.91%	+4.02%	-1.46%	-2.65%
RNA Avidity Biosciences	0.00%	+15.68%	-5.28%	+3.94%	+22.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASND Ascendis Pharma A/S	2.3627 of 5 stars	3.5	2.0	0.0	3.0	1.7	0.6
GMAB Genmab A/S	4.4438 of 5 stars	4.3	5.0	0.0	3.5	0.0	3.1
RDY Dr. Reddy's Laboratories	2.0043 of 5 stars	2.3	2.0	1.7	4.0	0.0	1.3
RNA Avidity Biosciences	2.8143 of 5 stars	4.5	2.0	0.0	3.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	2.93	Moderate Buy	$204.67	24.68% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	90.22% Upside
RDY Dr. Reddy's Laboratories	2.50	Moderate Buy	$17.00	23.10% Upside
RNA Avidity Biosciences	3.00	Buy	$66.69	116.25% Upside

Current Analyst Ratings Breakdown

Latest RNA, GMAB, RDY, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	ASND Ascendis Pharma A/S	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$205.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/9/2025	RNA Avidity Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/18/2025	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$168.00 ➝ $200.00
3/17/2025	RNA Avidity Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
3/17/2025	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
3/17/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
3/13/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
3/12/2025	RNA Avidity Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$72.00
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$363.64M	27.52	N/A	N/A	($1.88) per share	-87.31
GMAB Genmab A/S	$21.53B	0.63	$1.39 per share	14.80	$8.04 per share	2.56
RDY Dr. Reddy's Laboratories	$311.31B	0.04	$1.04 per share	13.25	$4.50 per share	3.07
RNA Avidity Biosciences	$10.90M	340.22	N/A	N/A	$6.76 per share	4.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$409.12M	-$7.10	N/A	683.96	N/A	-104.54%	N/A	-39.23%	5/1/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.74	11.83	11.57	2.65	36.30%	16.78%	13.79%	5/8/2025 (Estimated)
RDY Dr. Reddy's Laboratories	$668M	$0.63	21.99	16.84	N/A	17.25%	17.87%	12.32%	5/6/2025 (Estimated)
RNA Avidity Biosciences	-$212.22M	-$2.89	N/A	N/A	N/A	-2,772.45%	-27.66%	-24.56%	5/8/2025 (Estimated)

Latest RNA, GMAB, RDY, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.26	N/A	N/A	N/A	$5.17 billion	N/A
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	N/A	N/A	N/A	$2.63 million	N/A
5/6/2025	Q4 24/25	RDY Dr. Reddy's Laboratories	$0.20	N/A	N/A	N/A	$83.70 billion	N/A
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	N/A	N/A	N/A	$98.56 million	N/A
2/27/2025	Q4 2024	RNA Avidity Biosciences	-$0.76	-$0.80	-$0.04	-$0.80	$1.74 million	$2.97 million
2/12/2025	Q4 2024	ASND Ascendis Pharma A/S	-$1.32	-$0.68	+$0.64	-$0.68	$115.06 million	N/A
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.08	0.58%	N/A	12.70%	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	N/A	1.17	0.84
GMAB Genmab A/S	N/A	5.25	5.24
RDY Dr. Reddy's Laboratories	0.02	1.92	1.38
RNA Avidity Biosciences	N/A	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
GMAB Genmab A/S	7.07%
RDY Dr. Reddy's Laboratories	3.85%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
GMAB Genmab A/S	1.54%
RDY Dr. Reddy's Laboratories	2.00%
RNA Avidity Biosciences	3.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	640	60.97 million	36.41 million	Optionable
GMAB Genmab A/S	1,660	661.97 million	651.58 million	Optionable
RDY Dr. Reddy's Laboratories	24,800	834.77 million	818.05 million	Optionable
RNA Avidity Biosciences	190	120.21 million	114.92 million	Optionable

RNA, GMAB, RDY, and ASND Headlines

Recent News About These Companies

Marshall Wace LLP Has $4.74 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 27 at 4:13 AM | marketbeat.com

Raymond James Financial Inc. Takes Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 27 at 3:54 AM | marketbeat.com

Adage Capital Partners GP L.L.C. Sells 327,430 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

April 26 at 6:32 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Takes $1.60 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 25 at 4:52 AM | marketbeat.com

Silverarc Capital Management LLC Has $15.81 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 24 at 7:49 AM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Shares Up 5.7% - Should You Buy?

April 23, 2025 | marketbeat.com

Avoro Capital Advisors LLC Grows Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 23, 2025 | marketbeat.com

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 21, 2025 | prnewswire.com

Renaissance Technologies LLC Acquires 69,300 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

April 21, 2025 | marketbeat.com

Federated Hermes Inc. Decreases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 21, 2025 | marketbeat.com

Jump Financial LLC Acquires Shares of 95,575 Avidity Biosciences, Inc. (NASDAQ:RNA)

April 20, 2025 | marketbeat.com

Walleye Capital LLC Takes $2.67 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 20, 2025 | marketbeat.com

Alliancebernstein L.P. Cuts Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 16, 2025 | marketbeat.com

Avidity’s del-desiran for DM1 named orphan drug in Japan

April 16, 2025 | musculardystrophynews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by JPMorgan Chase & Co.

April 15, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by Brokerages

April 14, 2025 | marketbeat.com

ExodusPoint Capital Management LP Makes New $984,000 Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 13, 2025 | marketbeat.com

Geode Capital Management LLC Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 13, 2025 | marketbeat.com

Fmr LLC Trims Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 12, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low - Here's Why

April 12, 2025 | marketbeat.com

Dynamic Technology Lab Private Ltd Takes $402,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

April 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IAMGOLD Stock Climbs as Turnaround Story Gains Traction
By Jeffrey Neal Johnson | April 11, 2025
View IAMGOLD Stock Climbs as Turnaround Story Gains Traction
Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes
By Jeffrey Neal Johnson | April 8, 2025
View Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes
Top 3 S&P 500 Winners in a Losing Market
By Ryan Hasson | April 9, 2025
View Top 3 S&P 500 Winners in a Losing Market
2 Penny Stocks With $10 Potential
By Thomas Hughes | April 16, 2025
View 2 Penny Stocks With $10 Potential
2 Reasons to Buy Apple Stock and 1 Significant Risk
By Chris Markoch | April 2, 2025
View 2 Reasons to Buy Apple Stock and 1 Significant Risk

RNA, GMAB, RDY, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$164.15 +3.70 (+2.31%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$164.24 +0.09 (+0.05%)

As of 04/25/2025 06:37 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Genmab A/S NASDAQ:GMAB

$20.59 +0.05 (+0.24%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$21.24 +0.65 (+3.18%)

As of 04/25/2025 04:58 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Dr. Reddy's Laboratories NYSE:RDY

$13.81 -0.19 (-1.36%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$13.81 0.00 (0.00%)

As of 04/25/2025 07:45 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Avidity Biosciences NASDAQ:RNA

$30.84 -0.09 (-0.29%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$30.85 +0.01 (+0.03%)

As of 04/25/2025 04:27 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time